One Ring to rule them all? Flagship’s big bet on dominating gene therapy 2.0 attracts a $117M megaround
Over the last 18 months or so, gene therapy has come in for its comeuppance.
Long known for once-and-done boasting, staking claims for curative results on some of the most bitter diseases known to man, the field has been staggered by failure, evidence of waning effects and fears that efficacy could wicker and flame out. And given the therapies’ viral constructs, they could only be given once.
As a result, various companies have been working on different solutions. But at Flagship, which has been rethinking what thinking big is, there’s one still quite stealthy effort that aims to sweep aside the first generation of therapies and supplant it with something completely new.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.